Thomas Peter, MD
Nephrology · Uncasville, CTNPI 1952397549
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $368 of the $448 with a category attached, or 82.2%. 7 manufacturers reported payments, led by AbbVie at 30.2% of the total. Reporting peaked in 2021 at $156 and has fallen 97.4% since, to $4 in 2025. That places this record below the midpoint for nephrology clinicians in CT, where the typical reported total is $625.
Across 13 payments — averaging $34.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$135
- Medtronic$107
- Otsuka America Pharmaceutical, Inc.$61
- Amgen$48
- Travere Therapeutics, Inc.$48
- Baxter Healthcare$37
- plus $11 from 1 others
Across 29 payments — averaging $1145.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Travere Therapeutics, Inc.$33K
What the payments were for
- Food & beverage$36882%
- Education$8018%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 1 | $135 |
| Medtronic | 1 | $107 |
| Otsuka America Pharmaceutical, Inc. | 1 | $61 |
| Amgen | 2 | $48 |
| Travere Therapeutics, Inc. | 5 | $48 |
| Baxter Healthcare | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$448 in reported general payments places this provider in the 40th percentile of 144 nephrology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 57 | $69,966 |
| FarxigaDapagliflozin Propanediol | 29 | $35,491 |
| KerendiaFinerenone | 16 | $17,910 |
| Sevelamer Carbonate | 52 | $11,681 |
| LokelmaSodium Zirconium Cyclosilicate | 26 | $9,919 |
| Cinacalcet Hcl | 27 | $9,400 |
| Potassium Citrate ErPotassium Citrate | 30 | $3,330 |
| ProsolParenteral Amino Acid 20% No.1 | 20 | $3,179 |
| Calcitriol | 149 | $2,157 |
| Calcium Acetate | 28 | $1,886 |
| Losartan Potassium | 201 | $1,652 |
| Torsemide | 56 | $1,607 |
| Amlodipine Besylate | 193 | $1,296 |
| Chlorthalidone | 67 | $1,269 |
| Allopurinol | 113 | $1,069 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Uncasville
- Jay GinsbergUncasville$31K
- Robert AlpernNew Haven$4.9M
- Ari GellerBloomfield$209K
- Richard FormicaNew Haven$198K
- Stefan SomloNew Haven$111K
- James GavinTrumbull$103K
- Fredric FinkelsteinNew Haven$70K
- Justin BelcherNew Haven$59K
- David SimonOrange$59K
- Ladan GolestanehNew Haven$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.